Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

NCT00347919 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms, Breast

Interventions

DRUG: pazopanib (GW786034) 400 mg
DRUG: lapatinib (GW572016) 1500 mg
DRUG: lapatinib (GW572016) 1000 mg
DRUG: pazopanib (GW786034) 800 mg

Sponsor

GlaxoSmithKline